喉部肉毒毒素注射与痉挛性发声障碍患者工作效率的关联
这项前瞻性病例系列纳入101例在职痉挛性发声障碍成人,75例完成研究,在喉部肉毒毒素注射前和注射后1个月评估工作效率损害。基线WPAI工作效率损害为43%,注射后1个月降至22%,平均改善20%(95%CI 14%-27%),效应量0.74。
要点
- 在职痉挛性发声障碍患者基线存在明显嗓音相关工作效率损害。
- 喉部肉毒毒素注射后1个月工作效率损害显著改善。
- 女性工作效率损害可能更明显,但需独立验证。
核心结论
- 在职痉挛性发声障碍患者报告嗓音相关工作生产力损害,喉部肉毒毒素注射后1个月显著改善。
- 痉挛性发声障碍与嗓音相关工作生产力的关联在女性中似乎大于男性,但该探索性性别差异需独立验证。
研究设计与样本
- 前瞻性病例系列,2015年11月1日至2018年8月30日在2个喉科门诊连续纳入成人在职痉挛性发声障碍患者。
- 共101例入组,75例完成研究;完成者平均年龄55.7岁(SD 11.8),其中女性53例(71%)。
主要发现
- 完成者基线嗓音相关工作效率损害平均为43%(SD 27%),肉毒毒素注射后1个月为22%(SD 23%)。
- 注射后1个月工作效率损害平均改善20%(SD 27%;95%CI 14%-27%;效应量0.74)。
关键数值与推荐
- 主要结局为WPAI工作效率损害域,采用配对双尾t检验比较注射前与注射后1个月的变化。
- 探索性亚组分析采用多变量线性回归,调整人口学、合并症和嗓音使用变量。
临床怎么用
- 对在职痉挛性发声障碍患者,喉部肉毒毒素注射后1个月可评估嗓音相关工作生产力的改善。
- 临床可关注女性患者的工作生产力损害,但性别差异尚需进一步验证。
局限性
- 本研究为病例系列,未设对照组。
- 101例入组中仅75例完成研究,存在失访。
- 性别相关差异为探索性分析,需独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A disordered voice can affect an individual across both work and non-work-related life domains. There is insufficient research on the effect of spasmodic dysphonia or its treatment with botulinum neurotoxin (BoNT) injections on work productivity. OBJECTIVE: To assess whether employed patients with spasmodic dysphonia experience voice-related work productivity impairment before BoNT injection, and had a 10% or greater improvement in productivity 1 month after treatment with BoNT injection. DESIGN, SETTING, AND PARTICPANTS: This prospective case series carried out in 2 laryngology outpatient clinics from November 1, 2015, to August 30, 2018 included a consecutive sample of adult employed patients diagnosed with spasmodic dysphonia. Analysis was conducted between November 1, 2015, to July 31, 2018. EXPOSURES: Treatment with BoNT injection into the intrinsic laryngeal musculature. MAIN OUTCOMES AND MEASURES: Eligible participants completed the following validated outcomes instruments immediately before and 1 month after outpatient laryngeal BoNT injection: the Work Productivity and Activity Impairment instrument (WPAI), Voice Handicap Index (VHI), and WorkHoarse. Demographic, comorbidity, and occupational voice use data were also collected at baseline. The changes in outcome measures (primary, WPAI Work Productivity Impairment domain) were tested using a paired 2-tailed t test. Exploratory subgroup analyses were analyzed with multivariable linear regression, adjusting for demographic, comorbidity, and voice use variables. RESULTS: Of the 101 patients enrolled, 75 completed the study. The mean (SD) age of the 75 completing participants was 55.7 (11.8) years and 53 (71%) were women. The participants who completed the study had mean (SD) voice-related work productivity impairment of 43% (27%) at baseline and 22% (23%) at 1 month after BoNT injection (difference, 20% [27%] improvement; 95% CI, 14%-27%; effect size, 0.74). CONCLUSIONS AND RELEVANCE: This case series study found that employed patients with spasmodic dysphonia reported voice-related work productivity impairment, which improved significantly 1 month after treatment with BoNT injection. The association of spasmodic dysphonia with voice-related work productivity appeared greater in women than men with comparable outcomes with BoNT treatment, but this exploratory sex-associated difference requires independent validation.
引用
- Meyer TK, Spiekerman C, Kaye R, et al. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 34351425. doi:10.1001/jamaoto.2021.1745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。